INDV is the ticker symbol for Indivior Pharmaceuticals, Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks INDV with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is INDV a good stock to buy?

13F Pro's AI ranking engine scores INDV at 58.6/100, ranked #1,002 of 2,925 stocks on a composite quality score built from its SEC filings, covering profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for INDV is available at https://13fpro.ai/company/INDV. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source INDV data?

All Indivior Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Indivior Pharmaceuticals, Inc. files with the SEC under CIK 1625297. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Indivior Pharmaceuticals, Inc. INDV

NasdaqMid CapHealthcare

13F Pro quality score

Rank #1,002 of 2,925TOP 50%

Why it scores 59 Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$343.00M

Quarter to Jun 30

Net income

$122.00M

Quarter to Jun 30

Free cash flow

$222.00M

Quarter to Jun 30

Operating margin

46.7%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026

$4.98B total

BlackRock, Inc.

$767.65M+0.9%

VANGUARD PORTFOLIO MANAGEMENT LLC

$310.69M-4.0%

OAKTREE CAPITAL MANAGEMENT LP

$251.40MNew

VANGUARD CAPITAL MANAGEMENT LLC

$225.48M-1.6%

STATE STREET CORP

$204.82M+1.8%

FULLER & THALER ASSET MANAGEMENT, INC.

$189.39M+1.9%

Two Seas Capital LP

$142.76M-26.7%

MORGAN STANLEY

$139.33M-3.1%

FRANKLIN RESOURCES INC

$136.07M+2871.8%

GEODE CAPITAL MANAGEMENT, LLC

$129.68M+8.0%

Madison Avenue Partners, LP

$117.94M-33.4%

MANGROVE PARTNERS IM, LLC

$109.83M-2.4%

CITADEL ADVISORS LLC

$109.46M-25.4%

DRIEHAUS CAPITAL MANAGEMENT LLC

$94.33M+22.3%

MILLENNIUM MANAGEMENT LLC

$86.12M-54.3%

DIMENSIONAL FUND ADVISORS LP

$77.82M+42.4%

Invesco Ltd.

$75.62M+18.0%

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

$67.65M-46.8%

ARROWSTREET CAPITAL, LIMITED PARTNERSHIP

$67.37M-29.3%

Assenagon Asset Management S.A.

$63.22MNew

FEDERATED HERMES, INC.

$60.26M+20.6%

Newtyn Management, LLC

$53.58M-34.7%

Point72 Asset Management, L.P.

$51.31M+1217.3%

NORTHERN TRUST CORP

$50.95M+6.9%

CHARLES SCHWAB INVESTMENT MANAGEMENT INC

$50.25M+7.2%

See all 339 institutional holders →

What's Driving INDV's Business? Latest 10-Q Breakdown

29/29 datapoints verified

AI-extracted from the 10-Q filed 2026-08-03 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Net revenue grew 14% YoY to $343M on 22% SUBLOCADE growth in the US, while gross margin expanded to 85% even as the company discloses a pending all-stock merger with Supernus.

Biggest Revenue Drivers

Total U.S.$300M+17% YoY

Growth primarily driven by sales of SUBLOCADE in the U.S.

Rest of World$43M-7% YoY

Reflects exit from certain non-U.S. markets; company expects this trend to continue

Biggest Revenue Drivers

Total revenue: $343M+14% YoY

Total U.S.$300M+17% YoY

Growth primarily driven by sales of SUBLOCADE in the U.S.

Within Total U.S.

SUBLOCADE$238M+22% YoY

Driven by dispense unit volume growth (up 18%), gross-to-net benefits and favorable price mix

Sublingual & other (Film/other)$57M+10% YoY

Benefited from favorable Film gross-to-net adjustments, offset by decline in U.S. Film category share

PERSERIS$5M-35% YoY

Rest of World$43M-7% YoY

Reflects exit from certain non-U.S. markets; company expects this trend to continue

Largest Expense Items

Selling, general and administrative$122M-23% YoY

Decrease primarily driven by headcount reductions and cost savings related to corporate initiatives

Cost of sales$50M-3% YoY

Decrease attributable to a prior-year $10M SUBLOCADE inventory write-down, partly offset by ~$2M of inventory provisions tied to market exit activities

Research and development$12M-42% YoY

Reflects reduced R&D activity following decisions to cease Phase 3 development of INDV-6001 and not advance INDV-2000 internally

Margins: Gross margin rose to 85% from 83% a year ago, driven by SUBLOCADE volume growth and lower cost of sales, including a prior-year inventory write-down that did not recur.

Watch Items from the Filing

SUBLOCADE alone accounted for 74% of net revenue in Q2 2026, up from 69% a year earlier, deepening reliance on a single product.
Company entered an Agreement and Plan of Merger with Supernus on August 1, 2026 (all-stock merger of equals); a termination fee of $174M is payable by Indivior in certain circumstances.
Company ceased Phase 3 development of INDV-6001 and decided not to advance INDV-2000 internally, and states it is 'not currently pursuing any pipeline activities.'
Accrued litigation settlement expenses of $56M remain for opioid litigation, and the Dental MDL now covers approximately 1,967 cases naming ~26,307 plaintiffs.
Rest of World revenue declined 7% YoY to $43M due to exits from certain non-U.S. markets, a trend management expects to continue.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →

Key Metrics

Revenue

Q2 2026

EDGAR

Net Income

Q2 2026

EDGAR

EPS (Diluted)

Q2 2026

EDGAR

Operating Margin

Q2 2026

EDGAR

Free Cash Flow

Q2 2026

EDGAR

Debt/Equity

Q2 2026

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/INDV

Earnings Per Share

13fpro.ai/company/INDV

Loading ratio trend…

Indivior Pharmaceuticals, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Op. marginOperating margin
FY 2025	10-K	$1.2B	$210.0M	21.1%
FY 2024	10-K	$1.2B	$7.0M	3.2%
FY 2023	10-K	$1.1B	$-126.0M	-13.9%
FY 2022	10-K	$901.0M	$-44.0M	-9.0%
FY 2021	20-F	$791.0M	$205.0M	26.9%

About Indivior Pharmaceuticals, Inc. (INDV): stock profile, AI score and financials

Indivior Pharmaceuticals, Inc. (INDV) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INDV at 58.6/100 on a composite quality score built from its SEC filings, placing it at rank #1,002 of 2,925 stocks — the top half of the AI-ranked universe. INDV scores in the top quartile across balance sheet strength (97.8), profitability (89.6), institutional flow (81.5). Areas of concern include free cash flow (18.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 38.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Indivior Pharmaceuticals, Inc. reports quarterly revenue of $343.0M, net income of $122.0M, an operating margin of 46.7%. Top institutional holders of INDV by reported 13-F value include BlackRock, VANGUARD PORTFOLIO MANAGEMENT, OAKTREE CAPITAL MANAGEMENT, based on the most recent SEC filings. INDV trades on the Nasdaq exchange and files with the SEC under CIK 1625297. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INDV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Indivior Pharmaceuticals, Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1625297 →

Indivior Pharmaceuticals, Inc. INDV

Top Institutional Holders

What's Driving INDV's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Biggest Revenue Drivers

Largest Expense Items

Watch Items from the Filing

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

INDV key financials by period

INDV insiders

About Indivior Pharmaceuticals, Inc. (INDV): stock profile, AI score and financials

Indivior Pharmaceuticals, Inc. INDV

Top Institutional Holders

What's Driving INDV's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

INDV key financials by period

Companies similar to INDV

INDV insiders

About Indivior Pharmaceuticals, Inc. (INDV): stock profile, AI score and financials